Department of Neurology, Boston Children's Hospital, Harvard Medical School, 300 Longwood Ave, Boston, MA, 02115, USA.
Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Hum Genet. 2023 Dec;142(12):1755-1776. doi: 10.1007/s00439-023-02613-6. Epub 2023 Nov 14.
To investigate the genotype-to-protein-to-phenotype correlations of succinic semialdehyde dehydrogenase deficiency (SSADHD), an inherited metabolic disorder of γ-aminobutyric acid catabolism. Bioinformatics and in silico mutagenesis analyses of ALDH5A1 variants were performed to evaluate their impact on protein stability, active site and co-factor binding domains, splicing, and homotetramer formation. Protein abnormalities were then correlated with a validated disease-specific clinical severity score and neurological, neuropsychological, biochemical, neuroimaging, and neurophysiological metrics. A total of 58 individuals (1:1 male/female ratio) were affected by 32 ALDH5A1 pathogenic variants, eight of which were novel. Compared to individuals with single homotetrameric or multiple homo and heterotetrameric proteins, those predicted not to synthesize any functional enzyme protein had significantly lower expression of ALDH5A1 (p = 0.001), worse overall clinical outcomes (p = 0.008) and specifically more severe cognitive deficits (p = 0.01), epilepsy (p = 0.04) and psychiatric morbidity (p = 0.04). Compared to individuals with predictions of having no protein or a protein impaired in catalytic functions, subjects whose proteins were predicted to be impaired in stability, folding, or oligomerization had a better overall clinical outcome (p = 0.02) and adaptive skills (p = 0.04). The quantity and type of enzyme proteins (no protein, single homotetramers, or multiple homo and heterotetramers), as well as their structural and functional impairments (catalytic or stability, folding, or oligomerization), contribute to phenotype severity in SSADHD. These findings are valuable for assessment of disease prognosis and management, including patient selection for gene replacement therapy. Furthermore, they provide a roadmap to determine genotype-to-protein-to-phenotype relationships in other autosomal recessive disorders.
为了研究琥珀酸半醛脱氢酶缺乏症(SSADHD)的基因型-蛋白-表型相关性,这是一种γ-氨基丁酸分解代谢的遗传性代谢紊乱。对 ALDH5A1 变体进行了生物信息学和计算机诱变分析,以评估它们对蛋白质稳定性、活性部位和辅因子结合域、剪接以及同四聚体形成的影响。然后将蛋白质异常与经过验证的疾病特异性临床严重程度评分以及神经学、神经心理学、生物化学、神经影像学和神经生理学指标相关联。共有 58 名个体(1:1 男/女比例)受到 32 种 ALDH5A1 致病性变体的影响,其中 8 种是新的。与预测不能合成任何功能性酶蛋白的个体相比,那些预测只合成单一同四聚体或多种同和异四聚体蛋白的个体,ALDH5A1 的表达显著降低(p=0.001),整体临床结局更差(p=0.008),特别是认知缺陷更严重(p=0.01)、癫痫(p=0.04)和精神疾病发病率更高(p=0.04)。与预测没有蛋白或蛋白在催化功能上受损的个体相比,那些预测蛋白在稳定性、折叠或寡聚化方面受损的个体具有更好的整体临床结局(p=0.02)和适应技能(p=0.04)。酶蛋白的数量和类型(无蛋白、单一同四聚体或多种同和异四聚体)以及它们的结构和功能损伤(催化或稳定性、折叠或寡聚化),导致 SSADHD 表型严重程度不同。这些发现对于评估疾病预后和管理非常重要,包括基因替代疗法的患者选择。此外,它们为确定其他常染色体隐性疾病的基因型-蛋白-表型关系提供了路线图。